Cingulate Inc (CING) Stock Price, Quote & News

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1...

Industry: Biotechnology

Sector: Healthcare

Phone: 913 942 2300

Website: www.cingulate.com

Address:

1901 West 47th Place, Kansas City, United States

Disco_Vader Feb. 4 at 7:50 AM

Disco Vader to the $CING Bulls 💃🕺 My dear bulls—feel the Force and the rhythm. CING isn’t hype; it’s physics, biology, and timing. CTx-1301 is a true once-daily ADHD stimulant using Precision Timed Release—three clean pulses, all-day control, no booster chaos, no afternoon crash. Phase 3? Statistically significant in adults and kids. FDA already accepted the NDA under 505(b)(2), with PDUFA set for May 31, 2026—this is a remix of an already-approved drug, not a brand-new hope . Tiny ~7M float. No warrant Death Star. Minimal shorts. US patent catalyst ahead (EU patent already made it dance to $20). $10B US ADHD TAM, manufacturing and commercialization locked and loaded. I don’t force-choke timelines—but when the beat drops, this one moonwalks. Stay smooth. Stay long. May the funk be with you. 🪩🖤

0 · Reply

TheDenniSystem Feb. 4 at 5:00 AM

$CING

0 · Reply

thompske Feb. 4 at 2:49 AM

$CING 3522 Watchers. More will come, still early here.

2 · Reply

The_Baba_Yaga Feb. 3 at 8:36 PM

$CING

1 · Reply

Jumpingfox Feb. 3 at 7:42 PM

$CING Is anyone concerned that the issued warrants could keep the price of the stock low? This seems to be the outcome for MIST after approval.

1 · Reply

FireFoxF10 Feb. 3 at 5:55 PM

$CING $420.69... actually might not be a meme according to Bob

0 · Reply

MetalFistSlip Feb. 3 at 5:53 PM

$CING Here from SLS, only have a starter position. What’s y’all’s pt? 👀

1 · Reply

Disco_Vader Feb. 3 at 5:48 PM

$CING bob is strong with the force.

0 · Reply

Bob_Coyle Feb. 3 at 5:41 PM

$CING May 31st Coruscant time Trying to free up a bit more capital to hit my target number before it's too late.

1 · Reply

CitadelCEO69 Feb. 3 at 5:33 PM

$CING Dilution absorbed, finally some price appreciation ahead of commercialization!

0 · Reply

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Oct 23, 2025, 4:45 PM EDT - 3 months ago

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Sep 17, 2025, 8:45 AM EDT - 4 months ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Aug 21, 2025, 4:35 PM EDT - 5 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 19, 2025, 8:45 AM EDT - 6 months ago

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Aug 15, 2025, 9:00 AM EDT - 6 months ago

Cingulate Provides Management Team Update

Aug 6, 2025, 8:45 AM EDT - 6 months ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Jun 18, 2025, 8:00 AM EDT - 8 months ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

May 8, 2025, 4:30 PM EDT - 9 months ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Apr 9, 2025, 8:00 AM EDT - 10 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Mar 26, 2025, 5:00 PM EDT - 11 months ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Dec 23, 2024, 7:30 AM EST - 1 year ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Nov 7, 2024, 7:30 AM EST - 1 year ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Jun 28, 2024, 9:15 AM EDT - 1 year ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 25, 2024, 4:30 PM EDT - 1 year ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 9:20 AM EDT - 1 year ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

May 8, 2024, 7:00 AM EDT - 1 year ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Apr 30, 2024, 5:45 AM EDT - 1 year ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 16, 2024, 5:00 PM EDT - 1 year ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Mar 6, 2024, 6:45 AM EST - 2 years ago

Cingulate to Attend DCAT Week 2024 in New York City

Feb 13, 2024, 6:45 AM EST - 2 years ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 6, 2024, 4:15 PM EST - 2 years ago

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 2 years ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Jan 29, 2024, 8:00 AM EST - 2 years ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 6:45 AM EST - 2 years ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Dec 28, 2023, 7:19 AM EST - 2 years ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Jun 29, 2023, 8:00 AM EDT - 2 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 14, 2023, 3:45 PM EDT - 2 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 8, 2023, 7:00 AM EDT - 2 years ago

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

May 25, 2023, 3:55 PM EDT - 2 years ago

Cingulate to Present at 13th Annual LD Micro Invitational

Disco_Vader Feb. 4 at 7:50 AM

0 · Reply

TheDenniSystem Feb. 4 at 5:00 AM

$CING

0 · Reply

thompske Feb. 4 at 2:49 AM

$CING 3522 Watchers. More will come, still early here.

2 · Reply

The_Baba_Yaga Feb. 3 at 8:36 PM

$CING

1 · Reply

Jumpingfox Feb. 3 at 7:42 PM

$CING Is anyone concerned that the issued warrants could keep the price of the stock low? This seems to be the outcome for MIST after approval.

1 · Reply

FireFoxF10 Feb. 3 at 5:55 PM

$CING $420.69... actually might not be a meme according to Bob

0 · Reply

MetalFistSlip Feb. 3 at 5:53 PM

$CING Here from SLS, only have a starter position. What’s y’all’s pt? 👀

1 · Reply

Disco_Vader Feb. 3 at 5:48 PM

$CING bob is strong with the force.

0 · Reply

Bob_Coyle Feb. 3 at 5:41 PM

$CING May 31st Coruscant time Trying to free up a bit more capital to hit my target number before it's too late.

1 · Reply

CitadelCEO69 Feb. 3 at 5:33 PM

$CING Dilution absorbed, finally some price appreciation ahead of commercialization!

0 · Reply

FireFoxF10 Feb. 3 at 5:29 PM

$CING PAADUUUUFFAAAAAA

0 · Reply

stockchacing Feb. 3 at 3:31 PM

$CING such a great opportunity here... US patent coming, PDUFA until end of May 2026, ready for commercialization, increasing TAM - if only I could buy more...

2 · Reply

Manwiththeplan Feb. 3 at 2:32 PM

$CING this will go up coming month. The have cash now and pdufa dat end of may

0 · Reply

FatherofTrades Feb. 3 at 6:32 AM

$CING

0 · Reply

Disco_Vader Feb. 3 at 12:01 AM

$CING 13,400 shares in total. And still not enough! PT $20 first. $100+ by 2027

0 · Reply

TheSuper Feb. 2 at 9:55 PM

$AQST Just a bystander on this bio but I ABSOUTELY LOVE seeing the short's comments about the CRL... and the price going up. LOL just amazing. LOVE this for all you longs on here. Congrats! For those who are interested: My top picks for next 6 months $SLS and $CING.

0 · Reply